Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate

Author(s):  Wu George, Yeung Stanley, Chen Frank

Issue:  Jan/Feb 2017 - Volume 21, Number 1
View All Articles in Issue

Abstract:  Neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone combination therapy is the standard of care for the prevention of chemotherapy-induced nausea and vomiting. Herein, we describe the physical and chemical stability of an injectable emulsion of the Neurokinin-1 receptor antagonist rolapitant 185 mg in 92.5 mL (free base, 166.5 mg in 92.5 mL) admixed with either 2.5 mL of dexamethasone sodium phosphate (10 mg) or 5 mL of dexamethasone sodium phosphate (20 mg). Admixtures were prepared and stored in two types of container closures (glass and Crystal Zenith plastic bottles) and four types of intravenous administration tubing sets (or intravenous tubing sets). The assessment of the physical and chemical stability was conducted on admixtures packaged in bottled samples stored at room temperature (20°C to 25°C under fluorescent light) and evaluated at 0, 1, and 6 hours. For admixtures in intravenous tubing sets, the assessment of physicochemical stability was performed after 0 and 7 hours of storage at 20°C to 25°C, and then after 20 hours (total 27 hours) under refrigeration (2°C to 8°C) and protected from light. Physical stability was assessed by visually examining the bottle contents under normal room light and measuring turbidity and particulate matter. Chemical stability was assessed by measuring the pH of the admixture and determining drug concentrations through high-performance liquid chromatographic analysis. Results showed that all samples were physically compatible throughout the duration of the study. The admixtures stayed within narrow and acceptable ranges in pH, turbidity, and particulate matter. Admixtures of rolapitant and dexamethasone were chemically stable when stored in glass and Crystal Zenith bottles for at least 6 hours at room temperature, as well as in the four selected intravenous tubing sets for 7 hours at 20°C to 25°C and then for 20 (total 27 hours) hours at 2°C to 8°C. No loss of potency of any admixed component occurred in the samples stored at the temperature ranges studied.

Related Keywords: George Wu, PhD, Stanley Yeung, PharmD, Frank Chen, PhD, rolapitant, neurokinin-1 receptor antagonist, NK-1 inhibitor, 5-hydroxytryptamine-3 receptor antagonist, dexamethasone, 5-HT3 inhibitor, serotonin pathway, substance P/NK-1 pathway, drug combination, drug admixtures, chemotherapy-induced nausea and vomiting, emesis, storage containers, intravenous tubing sets, antiemetic agents, injectable emulsion compound, stability, compatibility

Related Categories: CANCER AND AIDS, GASTROENTEROLOGY, PARENTERALS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, STORAGE

Printer-Friendly Version




Download in electronic PDF format for $35

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Wu George, Yeung Stanley, Chen Frank Jan/Feb 2017 66-75 Buy
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Wu George, Yeung Stanley, Chen Frank Jan/Feb 2017 76-82 Buy
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride Wu George, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly Jan/Feb 2018 86-94 Buy
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection Wu George, Powers Dan, Yeung Stanley, Chen Frank Jan/Feb 2018 76-85 Buy
Compounded Pain Formulations: What is the Evidence? Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso Jul/Aug 2014 278-286 Buy
Dextromethorphan, an NMDA receptor antagonist, as a Treatment for Pain Mishkan Emilyn S Sep/Oct 2005 339-346 Buy
Granisetron 1-mg/mL Injection Allen Loyd V Jr Jan/Feb 2013 66 Buy
Imatinib 40-mg/mL Oral Suspension Allen Loyd V Jr Nov/Dec 2016 510 Buy
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi Jul/Aug 2015 295-300 Buy
Book Review: The NMDA Receptor Jones Marty Jan/Feb 2000 26-27 Buy